Circulating Tumor DNA in Early Breast Cancer

Дата публикации: 01-07-2026 00:00:00

This review examines the clinical utility of circulating tumor DNA assays for detecting minimal residual disease in patients with early-stage breast cancer.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Tissue-Free vs Tumor-Informed Circulating Tumor DNA Assays in Early Triple Negative Breast Cancer	0	12.99	13-08-2026
2	Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer	0	7	25-06-2026
3	PFS in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review	0	8.34	16-07-2026
4	No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection	0	5	22-06-2026
5	Cemiplimab and Fianlimab With Neoadjuvant Chemotherapy in Early-Stage High-Risk Breast Cancer	0	18.85	30-07-2026
6	Troponin Screening and Major Cardiovascular Adverse Events During ICI Therapy	0	7.02	21-07-2026
7	Familial Melanoma Genes and Cancer Risk Among Genomically Ascertained Individuals	0	6.31	01-07-2026
8	Regional differences in chemotherapy treatment for breast cancer may affect survival, Swedish study finds	0	6.96	13-08-2026
9	Prostate Cancer Mortality After Relabeling Low-Grade Prostate Cancer as Precancerous	0	9.66	01-07-2026
10	Less Can Be More by Circulating Tumor DNA Use in ERBB2 -Positive Breast Cancer	0	7	25-06-2026

Классификация: Наука. Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 9.02. Источник: archderm.jamanetwork.com.